Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: NNK-induced DNA methyltransferase 1 in lung tumorigenesis in A/J mice and inhibitory effects of (-)-epigallocatechin-3-gallate.

Authors: Jin, Huanyu; Chen, Jayson X; Wang, Hong; Lu, Gary; Liu, Anna; Li, Guangxun; Tu, Shuiping; Lin, Yong; Yang, Chung S

Published In Nutr Cancer, (2015)

Abstract: DNA methyltransferase 1 (DNMT1), a key enzyme mediating DNA methylation, is known to be elevated in various cancers, including the mouse lung tumors induced by the tobacco-specific carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). However, it is not known whether DNMT1 expression is induced right after NNK treatment and how DNMT1 expression varies throughout lung tumorigenesis. In the present study, we found that administration of NNK to A/J mice caused elevation of DNMT1 in bronchial epithelial cells at Days 1, 3, and 14 after NNK treatment. DNMT1 elevation at Day 1 was accompanied by an increase in phospho-histone H2AX (γ-H2AX) and phospho-AKT (p-AKT). At Weeks 5 to 20, NNK-induced DNMT1 in lung tissues was in lower levels than the early stages, but was highly elevated in lung tumors at Week 20. In addition, the early induction of p-AKT and γ-H2AX as well as cleaved caspase-3 in NNK-treated lung tissues was not detected at Weeks 5 to 20 but was elevated in lung tumors. In concordance with DNMT1 elevation, promoter hypermethylation of tumor suppressor genes Cdh13, Prdm2, and Runx3 was observed in lung tissues at Day 3 and in lung tumors. Treatment by EGCG attenuated DNMT1, p-AKT, and γ-H2AX inductions at Days 1 and 3 and inhibited lung tumorigenesis.

PubMed ID: 25437343 Exiting the NIEHS site

MeSH Terms: Animals; Anticarcinogenic Agents/therapeutic use*; Antineoplastic Agents, Phytogenic/therapeutic use; Bronchi/drug effects; Bronchi/metabolism; Bronchi/pathology; Carcinogenesis/chemically induced; Carcinogenesis/metabolism; Carcinogenesis/pathology; Carcinogens/antagonists & inhibitors; Carcinogens/toxicity; Catechin/analogs & derivatives*; Catechin/therapeutic use; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors*; DNA (Cytosine-5-)-Methyltransferases/chemistry; DNA (Cytosine-5-)-Methyltransferases/genetics; DNA (Cytosine-5-)-Methyltransferases/metabolism; DNA Methylation/drug effects; Dietary Supplements*; Female; Gene Expression Regulation, Enzymologic/drug effects; Gene Expression Regulation, Neoplastic*/drug effects; Lung Neoplasms/chemically induced; Lung Neoplasms/diet therapy; Lung Neoplasms/metabolism; Lung Neoplasms/prevention & control*; Lung/drug effects; Lung/metabolism*; Lung/pathology; Mice, Inbred A; Neoplasm Proteins/agonists; Neoplasm Proteins/antagonists & inhibitors; Neoplasm Proteins/genetics; Neoplasm Proteins/metabolism; Nitrosamines/antagonists & inhibitors; Nitrosamines/toxicity; Promoter Regions, Genetic/drug effects; Respiratory Mucosa/drug effects; Respiratory Mucosa/metabolism; Respiratory Mucosa/pathology

Back
to Top